Thermo Fisher Scientific Inc. (TMO) Stock
NYSETMO has an Alpha Score of 44 out of 100 (weak), computed on Oct 28, 2026 from 3 of 4 sub-scores. 39 members of Congress disclosed 103 trades in TMO since 2014: 54 purchases and 49 sales, most recently Dan Newhouse (sale, Jul 10, 2026). 8 of the hedge funds AlphaScala tracks reported TMO in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Viking Global Investors's at $971.34M. Company insiders reported 0 open-market buys and 93 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 37.1 and its net margin 15.0% (key statistics as of Oct 22, 2026).
What is TMO's Alpha Score?
How it works →Alpha Score of 44 reflects weak overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 28, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Thermo Fisher Scientific Inc. (TMO)?
Most recent: Dan Newhouse (sale, Jul 10, 2026); records start Aug 19, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Newhouse R-WA · House | 2026-07-10 | sale | $1k – $15k |
| Dwight Evans D-PA · House | 2026-05-07 | partial sale | $1k – $15k |
| Alan Armstrong R-OK · Senate | 2026-03-27 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-31 | sale | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | purchase | $1k – $15k |
| Lisa McClain R-MI · House | 2025-10-30 | sale | $1k – $15k |
| Val Hoyle D-OR · House | 2025-09-23 | sale | $1k – $15k |
| Kelly Morrison D-MN · House | 2025-08-19 | partial sale | $15k – $50k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded TMO, with filing lags →Which hedge funds own TMO?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Viking Global Investors Andreas Halvorsen | 1.94M | $971.34M | +16% |
| D.E. Shaw David Shaw | 642K | $321.69M | +112% |
| Citadel Ken Griffin | 575K | $288.28M | -33% |
| Point72 Steve Cohen | 278K | $139.25M | -21% |
| Millennium Management Israel Englander | 165K | $82.96M | +134% |
| Duquesne Family Office Stanley Druckenmiller | 19K | $9.63M | NEW |
| Bridgewater Associates Ray Dalio | 13K | $6.49M | -11% |
| Marshall Wace | 4K | $2.17M | -99% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Thermo Fisher Scientific Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 28, 26 | Britt Lisa P. | Sr. VP and Chief HR Officer | SELL | 2.8K | $2.0M |
| Aug 31, 26 | Pettiti Gianluca | President & COO | SELL | 400 | $246K |
| Aug 31, 26 | Pettiti Gianluca | President & COO | SELL | 3.7K | $2.3M |
| Aug 24, 26 | Casper Marc N | Chairman & CEO | SELL | 101 | $63K |
| Aug 24, 26 | Casper Marc N | Chairman & CEO | SELL | 33 | $21K |
| Aug 24, 26 | Casper Marc N | Chairman & CEO | SELL | 79 | $50K |
| Aug 24, 26 | Casper Marc N | Chairman & CEO | SELL | 62 | $39K |
| Aug 21, 26 | Casper Marc N | Chairman & CEO | SELL | 2.7K | $1.7M |
| Aug 21, 26 | Casper Marc N | Chairman & CEO | SELL | 3.0K | $1.9M |
| Aug 21, 26 | Casper Marc N | Chairman & CEO | SELL | 1.8K | $1.1M |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are TMO's key statistics?
Key statistics as of Oct 22, 2026
How does TMO's valuation compare with the Healthcare sector?
| Metric | TMO | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 37.1 | 27.1 | 97 |
| Net margin | 15.03% | 5.48% | 139 |
| Return on equity | 13.33% | 6.84% | 158 |
| Dividend yield (payers) | 0.29% | 1.62% | 50 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
What did Thermo Fisher Scientific Inc.'s latest SEC filings say?
Latest 3Thermo Fisher Scientific Completes Acquisition of Clario Holdings Inc on March 24 2026
On March 24, 2026, Thermo Fisher Scientific Inc. filed an 8-K report to formally announce the completion of its acquisition of Clario Holdings, Inc. The filing serves as a notification of this material corporate event. The company provided a press release as an exhibit to the filing, which details the finalization of the transaction. No additional financial terms or operational integration details were disclosed within the body of the 8-K filing itself, other than the confirmation of the completed acquisition.
- ›Thermo Fisher Scientific Inc. completed the acquisition of Clario Holdings, Inc.
- ›The transaction was officially finalized on March 24, 2026.
- ›The company issued a press release to confirm the closing of the deal.
Thermo Fisher Scientific Files 2025 Annual Report Detailing Financial Position and Debt
Thermo Fisher Scientific Inc. filed its 10-K for the fiscal year ended December 31, 2025. The filing provides a comprehensive overview of the company's financial structure, including its extensive portfolio of senior notes with varying maturity dates ranging from 2025 through 2049. The report outlines the company's operational segments, which include Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The company maintains a diverse capital structure, utilizing both fixed and floating-rate debt instruments to manage its long-term obligations. The filing includes detailed disclosures regarding property, plant, and equipment, as well as intangible assets such as customer relationships, developed technology, and trade names. The company continues to report revenue streams categorized by product and service offerings. The report also details the company's equity structure, including common stock, additional paid-in capital, and treasury stock, reflecting changes over the three-year period ending in 2025. Management continues to monitor restructuring costs and other non-operating income and expenses as part of its ongoing financial oversight.
- ›Detailed extensive schedule of senior notes with maturities extending to 2049.
- ›Maintained consistent reporting across four primary business segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
- ›Updated disclosures for property, plant, and equipment depreciation and amortization policies.
- ›Reported ongoing management of restructuring and other non-operating costs.
- ›Confirmed continued use of both product and service revenue classifications.
Thermo Fisher Scientific Issues $3.8 Billion in Senior Notes for Clario Acquisition
On February 12, 2026, Thermo Fisher Scientific Inc. completed a public offering of senior notes totaling $3.8 billion in aggregate principal amount. The offering consisted of four tranches: $1 billion of 4.215% notes due 2031, $750 million of 4.550% notes due 2033, $1.3 billion of 4.902% notes due 2036, and $750 million of 5.546% notes due 2046. The notes are general unsecured obligations of the company and rank equally with existing unsecured and unsubordinated indebtedness. The company expects net proceeds from the offering to be approximately $3.76 billion after accounting for underwriting discounts and estimated expenses. Thermo Fisher intends to use these proceeds primarily to fund a portion of the cash consideration for its previously announced acquisition of Clario Holdings, Inc. Pending the completion of the acquisition, which remains subject to customary closing conditions and regulatory approvals, the company may use the funds for general corporate purposes, including debt repayment, working capital, capital expenditures, or share repurchases. The indenture governing the notes includes standard covenants that restrict the company and its subsidiaries from incurring debt secured by liens on principal properties or engaging in certain sale and lease-back transactions. Additionally, the company is subject to change-of-control provisions that may require a repurchase offer at 101% of the principal amount if the notes are downgraded below investment grade by at least two of the three major rating agencies following a change of control.
- ›Issued $3.8 billion in senior notes across four tranches maturing between 2031 and 2046.
- ›Net proceeds of approximately $3.76 billion earmarked for the acquisition of Clario Holdings, Inc.
- ›Notes include change-of-control provisions requiring repurchase at 101% if accompanied by an investment-grade downgrade.
- ›Negative covenants restrict the company from placing liens on principal properties or engaging in certain sale and lease-back transactions.
TMO price chart
Powered by TradingViewWhat does Thermo Fisher Scientific Inc. do?
Thermo Fisher Scientific Inc. is a leading provider of life sciences solutions, analytical instruments, specialty diagnostics, laboratory products, and biopharma services worldwide. The company serves pharmaceutical and biotech companies, hospitals, clinical diagnostic labs, universities, research institutions, government agencies, and sectors including environmental, industrial, research and development, quality, and process control. Its Life Sciences Solutions segment delivers reagents, instruments, and consumables for biological and medical research, drug and vaccine discovery and production, and disease diagnosis. The Analytical Instruments segment supplies tools, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and industrial applications, as well as clinical labs. Additional offerings include lab products, services through brands like Fisher Scientific and Unity Lab Services, and biopharma capabilities via Patheon and PPD. Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts, supports customers across North America, Europe, and Asia-Pacific with innovative technologies and global distribution.